Tags

Type your tag names separated by a space and hit enter

Human kallikrein 11: an indicator of favorable prognosis in ovarian cancer patients.
Clin Biochem. 2004 Sep; 37(9):823-9.CB

Abstract

OBJECTIVES

Human kallikrein 11 (hK11) is a secreted serine protease, highly expressed in hormonally regulated tissues, including the prostate and the ovary. Our preliminary studies indicate that hK11 may represent a diagnostic and prognostic biomarker for ovarian cancer. The aim of the present study was to examine the prognostic value of hK11 expression in ovarian tumors.

METHODS

Using our established immunofluorometric assay, hK11 levels were quantified (ng per mg of total protein) in 134 ovarian tumor extracts and correlated with various clinicopathological variables and outcome [progression-free survival (PFS), overall survival (OS)], over a median follow-up period of 42 months.

RESULTS

hK11 concentration in ovarian tumor cytosols ranged from 0 to 155 ng/mg of total protein, with a median of 1.45 ng/mg. An optimal cutoff value of 6.3 ng/mg was selected to categorize tumors as hK11-positive or negative. hK11-positive tumors were most often of early stage (Stage I/II) and grade (G1/G2) (P < 0.05). Univariate analysis revealed that patients with hK11-positive tumors had a significantly longer PFS (HR of 0.39, P = 0.005) and OS (HR of 0.44, P = 0.033). Cox multivariate analysis indicated that hK11 was an independent prognostic indicator of PFS (HR of 0.47, P = 0.042). Kaplan-Meier survival curves further confirmed that women with hK11-positive tumors have longer PFS and OS (P = 0.003 and P = 0.028, respectively). Also, a weak positive correlation was found between the expression levels of tissue hK11 and tissue CA125 (rs = 0.508; P < 0.001).

CONCLUSIONS

These results further validate our initial findings that hK11 is an independent marker of favorable prognosis in ovarian cancer patients.

Authors+Show Affiliations

Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, M5G 1X5, Canada. ediamandis@mtsinai.on.caNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

15329323

Citation

Diamandis, Eleftherios P., et al. "Human Kallikrein 11: an Indicator of Favorable Prognosis in Ovarian Cancer Patients." Clinical Biochemistry, vol. 37, no. 9, 2004, pp. 823-9.
Diamandis EP, Borgoño CA, Scorilas A, et al. Human kallikrein 11: an indicator of favorable prognosis in ovarian cancer patients. Clin Biochem. 2004;37(9):823-9.
Diamandis, E. P., Borgoño, C. A., Scorilas, A., Harbeck, N., Dorn, J., & Schmitt, M. (2004). Human kallikrein 11: an indicator of favorable prognosis in ovarian cancer patients. Clinical Biochemistry, 37(9), 823-9.
Diamandis EP, et al. Human Kallikrein 11: an Indicator of Favorable Prognosis in Ovarian Cancer Patients. Clin Biochem. 2004;37(9):823-9. PubMed PMID: 15329323.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Human kallikrein 11: an indicator of favorable prognosis in ovarian cancer patients. AU - Diamandis,Eleftherios P, AU - Borgoño,Carla A, AU - Scorilas,Andreas, AU - Harbeck,Nadia, AU - Dorn,Julia, AU - Schmitt,Manfred, PY - 2003/11/11/received PY - 2004/04/26/revised PY - 2004/04/28/accepted PY - 2004/8/27/pubmed PY - 2005/2/23/medline PY - 2004/8/27/entrez SP - 823 EP - 9 JF - Clinical biochemistry JO - Clin. Biochem. VL - 37 IS - 9 N2 - OBJECTIVES: Human kallikrein 11 (hK11) is a secreted serine protease, highly expressed in hormonally regulated tissues, including the prostate and the ovary. Our preliminary studies indicate that hK11 may represent a diagnostic and prognostic biomarker for ovarian cancer. The aim of the present study was to examine the prognostic value of hK11 expression in ovarian tumors. METHODS: Using our established immunofluorometric assay, hK11 levels were quantified (ng per mg of total protein) in 134 ovarian tumor extracts and correlated with various clinicopathological variables and outcome [progression-free survival (PFS), overall survival (OS)], over a median follow-up period of 42 months. RESULTS: hK11 concentration in ovarian tumor cytosols ranged from 0 to 155 ng/mg of total protein, with a median of 1.45 ng/mg. An optimal cutoff value of 6.3 ng/mg was selected to categorize tumors as hK11-positive or negative. hK11-positive tumors were most often of early stage (Stage I/II) and grade (G1/G2) (P < 0.05). Univariate analysis revealed that patients with hK11-positive tumors had a significantly longer PFS (HR of 0.39, P = 0.005) and OS (HR of 0.44, P = 0.033). Cox multivariate analysis indicated that hK11 was an independent prognostic indicator of PFS (HR of 0.47, P = 0.042). Kaplan-Meier survival curves further confirmed that women with hK11-positive tumors have longer PFS and OS (P = 0.003 and P = 0.028, respectively). Also, a weak positive correlation was found between the expression levels of tissue hK11 and tissue CA125 (rs = 0.508; P < 0.001). CONCLUSIONS: These results further validate our initial findings that hK11 is an independent marker of favorable prognosis in ovarian cancer patients. SN - 0009-9120 UR - https://www.unboundmedicine.com/medline/citation/15329323/Human_kallikrein_11:_an_indicator_of_favorable_prognosis_in_ovarian_cancer_patients_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0009912004001195 DB - PRIME DP - Unbound Medicine ER -